Reply to: MalariaWorld Winner of Social Media Award Malaria Heroes
Congratulations. you deserve it!
Reply to: Research: Modelling the impact of declining insecticide resistance with mosquito age on malaria transmission
This is yet another article, this time a mathematical model, that shows that resistance as measured in 2-4 days old mosquitoes may not be very relevant for malaria transmission, because these young mosquitoes do not transfer malaria; once they are older, they have almost lost resistance; however, kdr and AChe- are target resistance, and not metabolic. So, why do they not have effect independent of age? I think the response is more complex. Detoxyfying mechanisms are always present, also in fully susceptible insects, but these almost disappear with age and THEN, the target mutations are not enough to protect the insect - just a thought.
Reply to: LLIN, new products and the impact of/ on insecticide resistance
Reply to: Tea against ACT: David against Goliath
The Roll Back Malaria (RBM) partnership, established in 1998 as part of a global drive to galvanize stronger action to curb malaria, is to restructure. In light of this restructuring and continued financial difficulties, the governing board has recommended disbanding the current RBM secretariat hosted by WHO in Geneva. The Board’s decision was prompted by a financial shortfall in the 2015 budget. RBM partners include WHO and other UN entities, notably UNDP, UNICEF and the World Bank, as well as foundations, private sector entities, non-governmental organizations, research and academic institutions, and development partners.
This info was posted on the WHO site on August 25 and on other webpages. But for many of us the information went unnoticed. A funeral without much mourning !
Whatever the reason, the disbanding probably was not because of a lack of funding. The following companies are members of the RBM Council (www.gbchealth.org) : BASF, Bayer, ExxonMomil, Giulin Pharmaceuticals, GSK, Kuehne&Nagel, Novartis, Sanofi, Sigma-Tau, Sumitomo, Syngenta, Tana Netting, Vestergard.
Maybe there was too much fiddling of data and the worldwide claim this summer that malaria incidence had been halved was too optimistic. In 2010 RBM had forecasted near-zero deaths by end of 2015 (www.reuters.com/article/2011/09/12). The same year RBM had claimed international funding had significantly increased since 2003.
But already in 2006 Roger Bates from AFM had stated that the joint venture of the World Bank and the World Heath Organization in Roll Back Malaria was a bad combination. International funders have probably started to demand how their money is spent and what good it really does.
Reply to: A randomized trial of the efficacy of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital, Cameroon
Etude très intéressante dont les résultats viennent confirmer la rapidité d'action de l'artésunate IV dans le traitement du paludisme grave. Mais le résumé n'affirme aucune donnée sur la mortalité.